Approval · Notice of Compliance 280 · 2004
RIVA-GABAPENTIN: Notice of Compliance 280
Issued March 24, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 280
- Date
- March 24, 2004
- Company
- Laboratoire Riva Inc.Blainville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Antiepileptic agent
- Canadian reference product
- NEURONTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RIVA-GABAPENTIN | 02251167 | Marketed |
| RIVA-GABAPENTIN | 02251175 | Marketed |
| RIVA-GABAPENTIN | 02251183 | Marketed |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP